Page 47 - AN-3-1

Advanced Neurology Antibodies as neurodegenerative biomarkers

doi: 10.1159/000517238 70. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat
Rev Dis Primers. 2017;3(1):17013.
60. Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s
disease: Pathogenesis, diagnostics, and therapeutics. Int J doi: 10.1038/nrdp.2017.13
Nanomedicine. 2019;14:5541-5554.
71. Bae EJ, Lee HJ, Rockenstein E, et al. Antibody-aided clearance
doi: 10.2147/IJN.S200490 of extracellular α-synuclein prevents cell-to-cell aggregate
transmission. J Neurosci. 2012;32(39):13454-13469.
61. Chandupatla RR, Flatley A, Feederle R, Mandelkow EM,
Kaniyappan S. Novel antibody against low-n oligomers of doi: 10.1523/JNEUROSCI.1292-12.2012
tau protein promotes clearance of tau in cells via lysosomes. 72. Nordström E, Eriksson F, Sigvardson J, et al. ABBV-0805, a
Alzheimers Dement (N Y). 2020;6(1):e12097.
novel antibody selective for soluble aggregated α-synuclein,
doi: 10.1002/trc2.12097 prolongs lifespan and prevents buildup of α-synuclein
pathology in mouse models of Parkinson’s disease. Neurobiol
62. Zilkova M, Nolle A, Kovacech B, et al. Humanized tau
antibodies promote tau uptake by human microglia without Dis. 2021;161:105543.
any increase of inflammation. Acta Neuropathol Commun. doi: 10.1016/j.nbd.2021.105543
2020;8(1):74.
73. Li X, Koudstaal W, Fletcher L, et al. Naturally occurring
doi: 10.1186/s40478-020-00948-z antibodies isolated from PD patients inhibit synuclein
seeding in vitro and recognize Lewy pathology. Acta
63. Congdon EE, Pan R, Jiang Y, et al. Single domain antibodies
targeting pathological tau protein: Influence of four Neuropathol. 2019;137(5):825-836.
IgG subclasses on efficacy and toxicity. EBioMedicine. doi: 10.1007/s00401-019-01974-5
2022;84:104249.
74. Cascella R, Perni M, Chen SW, et al. Probing the origin of
doi: 10.1016/j.ebiom.2022.104249 the toxicity of oligomeric aggregates of α-synuclein with
antibodies. ACS Chem Biol. 2019;14(6):1352-1362.
64. Lee SH, Le Pichon CE, Adolfsson O, et al. Antibody-mediated
targeting of tau in vivo does not require effector function doi: 10.1021/acschembio.9b00312
and microglial engagement. Cell Rep. 2016;16(6):1690-1700.
75. Näsström T, Gonçalves S, Sahlin C, et al. Antibodies against
doi: 10.1016/j.celrep.2016.06.099 alpha-synuclein reduce oligomerization in living cells. PLoS
One. 2011;6(10):e27230.
65. Nagele RG, Clifford PM, Siu G, et al. Brain-reactive
autoantibodies prevalent in human sera increase doi: 10.1371/journal.pone.0027230
intraneuronal amyloid-β(1-42) deposition. J Alzheimers Dis. 76. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM.
2011;25(4):605-622.
A possible role for humoral immunity in the pathogenesis of
doi: 10.3233/JAD-2011-110098 Parkinson’s disease. Brain. 2005;128(11):2665-2674.
66. Vojdani A, Vojdani E. Amyloid-beta 1-42 cross-reactive doi: 10.1093/brain/awh625
antibody prevalent in human sera may contribute to 77. Wang XJ, Yan ZQ, Lu GQ, Stuart S, Chen SD. Parkinson
intraneuronal deposition of A-Beta-P-42. Int J Alzheimers disease IgG and C5a-induced synergistic dopaminergic
Dis. 2018;2018:1672568.
neurotoxicity: Role of microglia. Neurochem Int.
doi: 10.1155/2018/1672568 2007;50(1):39-50.
67. Deng J, Hou H, Giunta B, et al. Autoreactive-Aβ antibodies doi: 10.1016/j.neuint.2006.07.014
promote APP β-secretase processing. J Neurochem. 78. Cao S, Theodore S, Standaert DG. Fcγ receptors are required
2012;120(5):732-740.
for NF-κB signaling, microglial activation and dopaminergic
doi: 10.1111/j.1471-4159.2011.07629.x neurodegeneration in an AAV-synuclein mouse model of
Parkinson’s disease. Mol Neurodegener. 2010;5(1):42.
68. Gold M, Mengel D, Röskam S, Dodel R, Bach JP. Mechanisms
of action of naturally occurring antibodies against β-amyloid doi: 10.1186/1750-1326-5-42
on microglia. J Neuroinflammation. 2013;10(1):5.
79. Choi YR, Cha SH, Kang SJ, Kim JB, Jou I, Park SM.
doi: 10.1186/1742-2094-10-5 Prion-like propagation of α-synuclein is regulated by
the FcγRIIB-SHP-1/2 signaling pathway in neurons. Cell
69. Valls-Comamala V, Guivernau B, Bonet J, et al. The antigen-
binding fragment of human gamma immunoglobulin Rep. 2018;22(1):136-148.
prevents amyloid β-peptide folding into β-sheet to form doi: 10.1016/j.celrep.2017.12.009
oligomers. Oncotarget. 2017;8(25):41154-41165.
80. Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease:
doi: 10.18632/oncotarget.17074 New insights into molecular pathogenesis and therapeutic

Volume 3 Issue 1 (2024) 12 https://doi.org/10.36922/an.2058